Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial | Zendy

Men-Tai Wu | Zendy; Shi-Cheng Tung | Zendy; Kao-Tai Hsu | Zendy; ChienTe Lee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial

Author(s) -

Men-Tai Wu,

Shi-Cheng Tung,

Kao-Tai Hsu,

ChienTe Lee

Publication year - 2012

Publication title -

journal of the renin-angiotensin-aldosterone system

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.457

H-Index - 46

eISSN - 1752-8976

pISSN - 1470-3203

DOI - 10.1177/1470320312467560

Subject(s) - aliskiren , medicine , proteinuria , urology , renal function , blood pressure , kidney disease , creatinine , diabetes mellitus , endocrinology , renin–angiotensin system , kidney

The combination therapy of aliskiren and renin-angiotensin-aldosterone system (RAAS) blocker in chronic kidney disease (CKD) is controversial. Whether such dual blockade can effectively apply to patients with CKD irrespective of stage and amount of proteinuria remains uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research